Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT07342868 | Recruiting Phase 1 FDA Drug

• 1 other identifier: ALG-000184-207
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).

Conditions

Chronic Hepaititis B Infections

Keywords

Chronic Hepaititis B Infections

Outcome Measures

Primary Outcomes (6)

• Area under the concentration time curve [AUC]

  PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma

  Up to 4 days

• Time to maximum plasma concentration [Tmax]

  PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma

  Update to 4 Days

• Maximum plasma concentration [Cmax]

  PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma

  Update to 4 days

• Minimum plasma concentration [Cmin]

  PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma

  Up to 4 days

• C0 (predose)

  PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma

  Up to 4 days

• Half-life [t1/2]

  PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma

  Up to 4 Days

Secondary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

  Up to 15 days

Study Arms (2)

Subjects with Hepatic Impairment

EXPERIMENTAL

Subjects with hepatic impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug.

Drug: Pevifoscorvir Sodium (ALG-000184)

Subjects without Hepatic impairment

EXPERIMENTAL

Subjects without hepatic impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug.

Drug: Pevifoscorvir Sodium (ALG-000184)

Interventions

Pevifoscorvir Sodium (ALG-000184) DRUG

Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium

Subjects with Hepatic Impairment; Subjects without Hepatic impairment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and Female between 18 and 75 years old
• BMI 17.5 to 40.0 kg/m\^2 and a total body weight \>50 kg (110 lb)
• Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non- sterile, male sexual partners agree to use highly effective contraceptive therapy
• Female subjects must have a negative serum pregnancy test at screening
• Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs and 12-lead electrocardiogram (ECG) assessment
• Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, gender
• Normal hepatic function with no known or suspected hepatic impairment
• Subject satisfies the criteria for Class B of the Child-Pugh classification (Child Pugh Scores 7-9 points) within 28 days of study drug administration
• A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, Fibroscan, computerized tomography scan, or magnetic resonance imaging (MRI)
• Stable hepatic impairment for at least 3 months prior to screening or second screening visit to demonstrate stability
• Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria

You may not qualify if:

• Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation
• Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease etc.
• Subjects with a history of clinically significant drug allergy
• Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use
• Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men
• Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up
• Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection. Subjects provided they met stable treatment criteria. Subjects with HIV infection may be eligible for moderate impairment cohort provided they met stable treatment criteria.
• Estimated creatinine clearance \<60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\] - Unless otherwise instructed by the Study Review Committee (SRC), CKD-EPI should not be corrected for subjects of African ancestry
• Bilirubin (total, direct) \>1.2× upper limit of normal (ULN) (unless Gilbert's is suspected)
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \> 1.2×ULN
• Grade ≥1 Hemoglobin
• Subjects with advanced ascites (Grade 3)
• Subjects with refractory encephalopathy as judged by the investigator.
• Subjects with esophageal variceal bleeding within the past 6 months prior to screening.
• Subjects with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.

Sponsors & Collaborators

• Aligos Therapeutics: lead

Study Sites (1)

Orlando Clinical Research Center

Orlando, Florida, 32809, United States

RECRUITING

Central Study Contacts

Jen Rito

CONTACT

(800) 466-6059; info@aligos.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex.

Study Record Dates

• First Submitted: December 15, 2025
• First Posted: January 15, 2026
• Study Start: January 30, 2026
• Primary Completion: April 20, 2026
• Study Completion: May 5, 2026
• Last Updated: February 4, 2026

Record last verified: 2026-02

Locations

US (1)